Ranbaxy to market Ethypharm's cardiovascular drug in India

18 September 2006

Ranbaxy will market the product under its brand name Storfib. The drug will address the need for effective management of mixed dyslipidemia, which is very common amongst the Indian population, Ranbaxy said in a filing with the BSE.

The product will be manufactured by Ethypharm at its facility near Mumbai.

"Ranbaxy in India, is the leader in novel drug delivery system (NDDS) and a pioneer in the lipids management portfolio. The launch of Storfib, which symbolises both these strengths, would further augment our leadership position in the cardio-vascular market," said Sanjeev I Dani, regional director, India and Middle East, Ranbaxy.

Combinational products are growing very fast in India and it is estimated that more than two thirds of all combination products worldwide are registered first in India. Ethypharm endeavours to ensure that the benefits of its drug delivery technologies also encompass such combinational products.

"This product encapsulates the benefits of both combination offerings and drug delivery technologies and will help the large Indian populace who suffer from combined (mixed) dyslipidemia which is common culprit in Asian subcontinent including India", said Ajey Kumar, chief executive officer of Ethypharm India.